| Patient | Irène Joliot-Curie |
|---|---|
| Date of birth | 1897-09-12 |
| Identifiers | MRN HR-RB003-SYN-TD; SSN (made up) 000-03-8841 |
| Document date | 1955-09-28 |
| Author | Solène Marchand-Ellis, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Genetic results, classification and risk, fitness for treatment, and the start of induction. [S]
Mrs. Joliot-Curie returns twelve days after the marrow biopsy to review the genetic results and decide on treatment. She has had blood counts twice a week; she felt better after the red cell transfusion but is tired again and now rests for part of each afternoon and has stopped going to the laboratory. No fever, bleeding beyond bruising, or infection. She had her echocardiogram, lung function tests and ECG earlier today. Her hepatitis B, hepatitis C and HIV tests were negative, and she is not immune to hepatitis B. She has read the trial reports on the treatment options and has questions. She met the palliative care team this morning. [S]
| Element | Detail |
|---|---|
| Symptoms | Tired, resting in the afternoons, off work; no fever |
| Results | Cytogenetics and molecular panel; echocardiogram; lung function; ECG |
| Infection screen | Hepatitis B, hepatitis C and HIV negative; not immune to hepatitis B |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; resting in the afternoons; no fever |
| Respiratory | Positive | Breathless on one flight of stairs; no cough |
| Integumentary | Positive | Bruises fading; no new ones |
| Psychiatric | Positive | Anxious about the results; sleeping six hours; PHQ-9 8, GAD-7 8 |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycle | Once daily on days 1 to 7 of each 28-day cycle | Subcutaneous route | 1955-09-28 | active | S |
| Venetoclax 10 mg oral tablet, cycle 1: 10 mg on day 1 and 20 mg on day 2, then two tablets (20 mg) daily with the 50 mg tablet from day 4 (70 mg a day, reduced for posaconazole) | Ramp-up, then two tablets daily with the 50 mg tablet, with food and water | Oral route | 1955-09-28 to 1955-10-19 | completed | S |
| Venetoclax 50 mg oral tablet, cycle 1: one tablet alone on day 3 (50 mg), then one tablet daily with two 10 mg tablets from day 4 (70 mg a day) | One tablet daily from day 3, with food and water | Oral route | 1955-09-28 to 1955-10-19 | completed | S |
| Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic | 300 mg twice on day 1, then 300 mg once daily with food | Oral route | 1955-09-28 | active | S |
| Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxis | One tablet twice daily | Oral route | 1955-09-28 | active | S |
| Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5 | One tablet daily during profound neutropenia | Oral route | 1955-09-28 to 1955-10-30 | completed | S |
| Allopurinol 300 mg oral tablet, one tablet daily for tumor lysis prophylaxis during cycle 1 | One tablet daily | Oral route | 1955-09-28 to 1955-10-19 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1955-09-28 | Body height | 163 | cm | S |
| 1955-09-28 | Body weight | 53.5 | kg | S |
| 1955-09-28 | Body mass index (BMI) [Ratio] | 20.1 | kg/m2 | S |
| 1955-09-28 | Systolic blood pressure | 116 | mm[Hg] | S |
| 1955-09-28 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1955-09-28 | Heart rate | 92 | /min | S |
| 1955-09-28 | Respiratory rate | 16 | /min | S |
| 1955-09-28 | Body temperature | 36.9 | Cel | S |
| 1955-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1955-09-28 | Leukocytes [#/volume] in Blood by Automated count | 1.6 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1955-09-28 | Neutrophils [#/volume] in Blood by Automated count | 0.4 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 1955-09-28 | Hemoglobin [Mass/volume] in Blood | 8.6 | g/dL | 12-15.5 g/dL | Low | S |
| 1955-09-28 | Platelets [#/volume] in Blood by Automated count | 18 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1955-09-28 | Blasts/Leukocytes in Blood by Manual count | 16 | % | None seen normally | High | S |
| 1955-09-28 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1955-09-28 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1955-09-28 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 1955-09-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M | 85 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1955-09-28 | Calcium [Mass/volume] in Serum or Plasma | 9.1 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1955-09-28 | Phosphate [Mass/volume] in Serum or Plasma | 3.6 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 1955-09-28 | Urate [Mass/volume] in Serum or Plasma | 5.8 | mg/dL | 2.6-6 mg/dL | Normal | S |
| 1955-09-28 | Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma | 448 | U/L | 140-280 U/L | High | S |
| 1955-09-28 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-35 U/L | Normal | S |
| 1955-09-28 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1955-09-28 | Diffusion capacity.carbon monoxide/Predicted | 58 | % | 80% of predicted or more | Low | S |
| 1955-09-28 | FEV1 measured/predicted | 76 | % | >=80% | Low | S |
| 1955-09-28 | Left ventricular Ejection fraction | 62 | % | 55-70% | Normal | S |
| 1955-09-28 | Q-T interval corrected | 428 | ms | Above 460 ms is prolonged in women | Normal | S |
| 1955-09-28 | ECOG Performance Status score | 2 | {score} | S | ||
| 1955-09-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 1955-09-28 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S |
Vital signs recorded on 1955-09-28; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Tired, alert and composed; weight 53.5 kg; ECOG 2 |
| Mouth | No ulcers, thrush or gum swelling |
| Respiratory | Fine crackles at the right apex; otherwise clear |
| Abdomen | No enlarged liver or spleen |
| Skin | Fading bruises |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Two months of tiredness, easy bruising and bleeding gums, with pancytopenia and 12 percent blasts on the blood smear; acute leukemia suspected and urgent hematology review booked | resolved | confirmed | D61.818 | S — Synthetic presenting concern at the index visit, superseded by the bone marrow diagnosis two days later; its timing echoes the documented decline in her health (D). |
| Acute myeloid leukemia diagnosed on bone marrow biopsy (34 percent myeloblasts), in a physicist with decades of occupational exposure to ionizing radiation; synthetic modern diagnosis linked to her documented leukemia | active | confirmed | C92.00 | S — Synthetic modern diagnosis and subtype; the type of her real leukemia is not documented. |
| Occupational exposure to ionizing radiation over about four decades: X-ray work early in her career, laboratory work with polonium and other radioactive sources, and a laboratory accident in which a sealed polonium source ruptured on her bench about ten years ago | active | confirmed | Z57.1 | S — Synthetic modern coding of her documented occupational exposure. |
| Pulmonary tuberculosis in her forties, treated to completion; no symptoms of active disease | active | confirmed | Z86.11 | S — Synthetic modern coding of her documented tuberculosis; the treatment details are synthetic. |
| Moderately reduced lung gas transfer (DLCO 58 percent of predicted, FEV1 76 percent) from old tuberculous scarring of the right upper lobe; with performance status 2, it makes her unfit for intensive induction | active | confirmed | R94.2 | S — Synthetic finding on pre-treatment testing. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with differential and smear | At diagnosis; two to three times a week during induction; before each cycle | Completed today | White cells 1.6, neutrophils 0.4, hemoglobin 8.6 g/dL after one unit, platelets 18 x10^3/uL, blasts 16% |
| Laboratory | Bone marrow: morphology, flow cytometry, cytogenetics, molecular panel | At diagnosis; day 21 to 28 of cycle 1; then as response and transplant planning require | Completed today | Complex karyotype with del(5q), -7 and -17; TP53 mutation, VAF 41%; no NPM1, FLT3, IDH1, IDH2 or CEBPA mutation: WHO 1951 AML, myelodysplasia-related; ICC 1951 AML with mutated TP53; ELN 1951 adverse |
| Laboratory | Chemistry: electrolytes, creatinine, calcium, phosphate, uric acid, LDH, liver tests | At diagnosis; during venetoclax ramp-up for tumor lysis; then weekly in cycle 1 and before each cycle | Completed today | Sodium 140, potassium 4.1 mmol/L; creatinine 0.80 mg/dL, eGFR 85; calcium 9.1, phosphate 3.6, uric acid 5.8 mg/dL; LDH 448 U/L; ALT 24 U/L, bilirubin 0.7 mg/dL; tumor lysis labs every 6 to 8 hours in hospital during the ramp-up |
| Imaging | Fitness: performance status, comorbidity (HCT-CI), echocardiogram, lung function | Before choosing induction | Completed today | ECOG 2; DLCO 58% and FEV1 76% of predicted; ejection fraction 62%; HCT-CI 3: unfit for intensive induction by the VIALE-A criteria |
| Medication safety | Azole safety: posaconazole interactions (venetoclax dose), liver tests, QTc, trough level | At start; liver tests weekly; trough level after about a week of dosing; QTc with any added QT-prolonging drug | Completed today | Baseline QTc 428 ms and liver tests normal; venetoclax set at 70 mg for posaconazole, a strong CYP3A inhibitor |
| Medication safety | Transfusion support: thresholds, irradiated and leukoreduced products | At each blood count | Completed today | No transfusion needed today; irradiated, leukoreduced products flagged in the blood bank |
| Self-management | Infection prophylaxis and the fever plan | Throughout neutropenia | Completed today | Posaconazole, acyclovir and levofloxacin start today; fever plan reviewed |
| Laboratory | Hepatitis B, hepatitis C and HIV testing before therapy | Once, before therapy | Completed today | Hepatitis B surface antigen, core antibody and surface antibody negative; hepatitis C and HIV negative: no hepatitis B prophylaxis needed |
| Referral | HLA typing and allogeneic transplant evaluation | At diagnosis | Completed today | HLA typing complete; transplant center evaluation and unrelated donor search started |
| Referral | Specialist palliative care: symptoms, prognosis, goals and values | From diagnosis, at every visit | Completed today | First palliative care visit this morning: symptoms, her understanding of the prognosis, and her goals |
| Survey | Distress, depression and anxiety screening | At diagnosis and at each phase of treatment | Completed today | PHQ-9 8, GAD-7 8: mild; supported by the palliative care team |
| Self-management | Occupational exposure history and dose records | Until the records are received | Due | Written request sent; records awaited |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022 (PMID 35797463) (2022); Khoury JD, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022 (PMID 35732831) (2022); Arber DA, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022 (PMID 35767897) (2022); DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (VIALE-A). N Engl J Med 2020 (PMID 32786187) (2020); NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026); Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: ASCO and IDSA Clinical Practice Guideline Update (PMID 29461916) (2018); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024 (PMID 38748941) (2024); Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023); Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (PMID 32716741) (2020); 10 CFR 19.13, Notifications and reports to individuals (radiation exposure reports on request) (2026); 29 CFR 1910.1096, Ionizing radiation (records of exposure and disclosure to employees) (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: In hospital for the venetoclax ramp-up, then twice-weekly blood counts with transfusion as needed. Bone marrow on day 21 to 28. Palliative care and transplant center visits during cycle 1. Emergency department at once for a temperature of 38.0 °C or more. Next scheduled visit 1955-10-19: day 22 of cycle 1: bone marrow response, transfusion and infection review, and stopping venetoclax for count recovery. [S]